[
Abstract]
[
Full Text PDF] （in Japanese / 2029KB）
[Members Only And Two Factor Auth.] J.Jpn. Surg. Soc.. 92(9): 1237-1240, 1991
Report on the annual meeting
THE CANCER IMMUNOTHERAPY CONTROLLED BY THE NUMBER OF PHA-BLASTOGENIC CELLS
Old BRMs have been conventionally evaluated by comparative studies between the cancer patients treated with or without BRMs. This comparison should be done under the assumption that effectiveness of BRMs is dose-dependent. However BRMs can not be effective without enhancing cellular immunity of the patients. We have demonstrated that PHA blastogenic reaction was not necessarily augmented in vitro in a dose-related manner by MRMs. Nor did the dose-dependent immuno-enhancement always occur by clinical use of BMRs, if the blastogenic ratio was converted to the number of blastgenic cells per mm
3 of peripheral blood to monitor the patient's cellular immunity more precisely. If BRMs should be reviewed in terms of the immuno-enhancing activity by the number of PHA blastogenic cells, the clinical needs of BRMs must be increased. It is sure that the patient's survival could be improved if immunotherapy should be done with varying a dosis or schedule individually by using the adequate immunoparameters such as PHA blastogenic reaction.
To read the PDF file you will need Adobe Reader installed on your computer.